The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Emily Sonestedt

Emily Sonestedt

Associate senior lecturer

Emily Sonestedt

Circulating isoflavone and lignan concentrations and prostate cancer risk : a meta-analysis of individual participant data from seven prospective studies including 2,828 cases and 5,593 controls


  • Aurora Perez-Cornago
  • Paul N. Appleby
  • Heiner Boeing
  • Leire Gil
  • Cecilie Kyrø
  • Fulvio Ricceri
  • Neil Murphy
  • Antonia Trichopoulou
  • Konstantinos K. Tsilidis
  • Kay Tee Khaw
  • Robert N. Luben
  • Randi E. Gislefoss
  • Hilde Langseth
  • Isabel Drake
  • Emily Sonestedt
  • Peter Wallström
  • Pär Stattin
  • Anders Johansson
  • Rikard Landberg
  • Lena Maria Nilsson
  • Kotaro Ozasa
  • Akiko Tamakoshi
  • Kazuya Mikami
  • Tatsuhiko Kubo
  • Norie Sawada
  • Shoichiro Tsugane
  • Timothy J. Key
  • Naomi E. Allen
  • Ruth C. Travis

Summary, in English

Phytoestrogens may influence prostate cancer development. This study aimed to examine the association between prediagnostic circulating concentrations of isoflavones (genistein, daidzein, equol) and lignans (enterolactone and enterodiol) and the risk of prostate cancer. Individual participant data were available from seven prospective studies (two studies from Japan with 241 cases and 503 controls and five studies from Europe with 2,828 cases and 5,593 controls). Because of the large difference in circulating isoflavone concentrations between Japan and Europe, analyses of the associations of isoflavone concentrations and prostate cancer risk were evaluated separately. Prostate cancer risk by study-specific fourths of circulating concentrations of each phytoestrogen was estimated using multivariable-adjusted conditional logistic regression. In men from Japan, those with high compared to low circulating equol concentrations had a lower risk of prostate cancer (multivariable-adjusted OR for upper quartile [Q4] vs. Q1 = 0.61, 95% confidence interval [CI] = 0.39–0.97), although there was no significant trend (OR per 75 percentile increase = 0.69, 95 CI = 0.46–1.05, ptrend = 0.085); Genistein and daidzein concentrations were not significantly associated with risk (ORs for Q4 vs. Q1 = 0.70, 0.45–1.10 and 0.71, 0.45–1.12, respectively). In men from Europe, circulating concentrations of genistein, daidzein and equol were not associated with risk. Circulating lignan concentrations were not associated with the risk of prostate cancer, overall or by disease aggressiveness or time to diagnosis. There was no strong evidence that prediagnostic circulating concentrations of isoflavones or lignans are associated with prostate cancer risk, although further research is warranted in populations where isoflavone intakes are high.


  • Diabetes - Cardiovascular Disease
  • EpiHealth: Epidemiology for Health
  • EXODIAB: Excellence of Diabetes Research in Sweden
  • Nutrition Epidemiology

Publishing year







International Journal of Cancer





Document type

Journal article


John Wiley & Sons Inc.


  • Cancer and Oncology


  • isoflavones
  • lignans
  • phytoestrogens
  • pooled analysis
  • prostate cancer risk



Research group

  • Diabetes - Cardiovascular Disease
  • Nutrition Epidemiology


  • ISSN: 0020-7136